Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment

Toxicology and Applied Pharmacology

Volumn 251, Issue 1, 2011, Pages 32-40

  Vilà, Laia ^a   Rebollo, Alba ^a   Adalsteisson, Gunnar S ^a   Alegret, Marta ^a,b   Merlos, Manuel ^a,b   Roglans, Nuria ^a,b   Laguna, Juan C ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

ChREBP; Fatty acid oxidation; NAFLD; NF B

Indexed keywords

ATORVASTATIN; FRUCTOKINASE; FRUCTOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER PROTEIN; METALLOTHIONEIN I; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEVERAGE; BLOOD SAMPLING; CATABOLISM; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME BLOOD LEVEL; EXPERIMENTAL MODEL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FOOD INTAKE; GENE EXPRESSION; HEPATITIS; HYPERLEPTINEMIA; HYPERTRIGLYCERIDEMIA; LIVER; LIVER HISTOLOGY; LIVER METABOLISM; LIVER NECROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FATTY ACIDS; FATTY LIVER; FRUCTOKINASES; FRUCTOSE; GENE EXPRESSION REGULATION; HEPATITIS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIVER; MALE; METALLOTHIONEIN; NECROSIS; NF-KAPPA B; OXIDATION-REDUCTION; PHOSPHORYLATION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

RATTUS;

EID: 78751615734     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.11.011     Document Type: Article

References (41)

1. Ahmed M.H., Byrne C.E. Current treatment of non-alcoholic fatty liver disease. Diab. Obes. Metab. 2009, 11:188-195.
2. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Issacshon J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc. 1996, 275:128-133.
3. Bradford M.M. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
4. Browning J.D. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006, 44:466-471.
5. Caballería Ll., Pera G., Auladell M.A., Torán P., Muñoz L., Miranda D., Alumà A., Casas J.D., Sánchez C., Gil D., Aubà J., Tibau A., Canut S., Bernard J., Aizpurua M.M. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur. J. Gastroenterol. Hepatol. 2010, 22:24-32.
6. Cosentino F., Assenza G.E. Diabetes and inflammation. Hertz 2004, 29:749-759.
7. Elliott S.S., Keim N.L., Stern J.S., Teff K., Havel P.J. Fructose, weight gain, and insulin resistance syndrome. Am. J. Clin. Nutr. 2002, 76:911-922.
8. Fabbrini E., Sullivan S., Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010, 51:679-689.
9. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
10. Gómez-Domínguez E., Gisbert J.P., Moreno-Monteagudo J.A., García-Buey L., Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemic, non-alcoholic fatty liver patients. Aliment. Pharmacol. Ther. 2006, 23:1643-1647.
11. Helenius M., Hänninen M., Lehtinen S.K., Salminen A. Aging-induced up-regulation of nuclear binding activities of oxidative stress responsive NFΚB transcription factor in mouse cardiac muscle. J. Mol. Cell. Cardiol. 1996, 28:487-498.
12. Hellerstein M.K. Carbohydrate-induced hypertriglyceridemia: modifying factors and implications for cardiovascular risk. Curr. Opin. Lipidol. 2002, 13:33-40.
13. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M., Mastunaga T., Hayashi K., Awata T., Komoda T., Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARαRXRΚ and decrease the transactivation of NFΚB. Biochem. Biophys. Res. Commun. 2002, 290:131-139.
14. Isomaa B., Almgreen P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskin M.R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care 2001, 24:683-689.
15. Katagiri H., Yamada T., Oka Y. Adiposity and cardiovascular disorders. Disturbance of the regulatory system consisting of humoral and neuronal signals. Circ. Res. 2007, 101:27-39.
16. Kiyici M., Gulten M., Gurel S., Giray Nak S., Dolar E., Savci G., Balaban Adim S., Yerci O., Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 2003, 17:713-718.
17. Korieh A., Crouzoulon G. Dietary regulation of fructose metabolism in the intestine and in the liver of the rat. Duration of the effects of a high fructose diet after the return to the standard diet. Arch. Int. Physiol. Biochym. Biophys. 1991, 99:455-460.
18. Lazarow P.B. Assay of peroxisomal ß-oxidation of fatty acids. Meth. Enzymol. 1981, 72:315-319.
19. Lea A.P., McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997, 53:828-847.
20. Li M., Carpio D.F., Zheng Y., Bruzzo P., Singh V., Ouaaz F., Medzhitov R.M., Beg A.A. An essential role of the NFΚB/Toll like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immnunol. 2001, 166:7128-7135.
21. Magnani M., Crinelli R., Bianchi M., Antonelli A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr. Drug Targets 2000, 1:387-399.
22. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., Najib-Fruchart J., Glineur C., Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J. Clin. Invest. 2001, 107:1423-1432.
23. Ortego M., Bustos C., Hernández-Presa M.A., Tuñón J., Díaz C., Hernández G., Egido J. Atorvastatin reduces NF-ΚB activation and chemokine expression in vascular smooth muscle cells and monocuclear cells. Atherosclerosis 1999, 147:253-261.
24. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., Johnson R.J., Abdelmalek M.F. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 2008, 48:993-999.
25. Park J., Lemieux S., Lewis G.F., Kuksis A., Steiner G. Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats. J. Lipid Res. 1997, 38:2529-2536.
26. Planavila A., Laguna J.C., Vázquez-Carrera M. Nuclear factor kappa B activation leads to down regulation of fatty acid oxidation during cardiac hypertrophy. J. Biol. Chem. 2005, 280:17464-17471.
27. Preiss D., Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. 2009, 70:815-828.
28. Rodríguez-Calvo R., Barroso E., Serrano L., Coll T., Sánchez R.M., Merlos M., Palomer X., Laguna J.C., Vázquez-Carrera M. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology 2009, 49:106-115.
29. Roglans N., Sanguino E., Peris C., Alegret M., Vázquez M., Adzet T., Díaz C., Hernández G., Laguna J.C., Sánchez R.M. Atorvastatin treatment induced peroxisome proliferator-activated receptor expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J. Pharmacol. Exp. Ther. 2002, 302:232-239.
30. Roglans N., Vilà L., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C. Impairment of hepatic STAT-3 activation and reduction of PPARα activity in fructose-fed rats. Hepatology 2007, 45:778-788.
31. Sanguino E., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C. Atorvatatin reverses the age-related reduction in rat hepatic PPARα by increasing the expression and binding activity of the transcription factor HNF-4. Br. J. Pharmacol. 2005, 145:853-861.
32. Segal M.S., Gollub E., Johnson R.J. Is the fructose index more relevant with regards to cardiovascular disease than the glycemic index?. Eur. J. Nutr. 2007, 46:406-417.
33. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 1998, 81:66B-69B.
34. Stienstra R., Mandard S., Patsouris D., Maass C., Kersten S., Müller M. Peroxisome proliferator-activated receptor α protects against obesity-induced hepatic inflammation. Endocrinology 2007, 148:2753-2763.
35. Tappy L., Lê K.-M. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010, 90:23-46.
36. Tessari P., Coracina A., Cosma A., Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2009, 19:291-302.
37. Tomita K., Azuma T., Kitamura N., Nishida J., Tamiya G., Oka A., Inokuchi S., Nishimura T., Suematsu M., Ishii H. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 2004, 126:873-885.
38. Uyeda K., Repa J.J. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006, 4:107-110.
39. Uyeda K., Yamashita H., Kawaguchi T. Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage. Biochem. Pharmacol. 2002, 63:2075-2080.
40. Vilà L., Roglans N., Alegret M., Sánchez R.M., Vázquez-Carrera M., Laguna J.C. Suppressor of cytokine signaling-3 (SOCS-3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. Hepatology 2008, 48:1506-1516.
41. Vilà L., Roglans N., Perna V., Sánchez R.M., Vázquez-Carrera M., Alegret M., Laguna J.C. Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose. J. Nutr. Biochem. 2010, 2010 Nov 5. (Epub ahead of print).